- Home
- CRGX vs WHF Comparison
CRGX vs WHF Comparison
Compare CRGX & WHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- WHF
- Stock Information
- Founded
- CRGX 2021
- WHF 2011
- Country
- CRGX United States
- WHF United States
- Employees
- CRGX N/A
- WHF N/A
- Industry
- CRGX
- WHF Finance Companies
- Sector
- CRGX
- WHF Finance
- Exchange
- CRGX Nasdaq
- WHF Nasdaq
- Market Cap
- CRGX 207.5M
- WHF 207.1M
- IPO Year
- CRGX 2023
- WHF 2012
- Fundamental
- Price
- CRGX $4.54
- WHF $8.48
- Analyst Decision
- CRGX Hold
- WHF Hold
- Analyst Count
- CRGX 7
- WHF 4
- Target Price
- CRGX $5.33
- WHF $10.00
- AVG Volume (30 Days)
- CRGX 1.7M
- WHF 74.9K
- Earning Date
- CRGX 08-06-2025
- WHF 08-07-2025
- Dividend Yield
- CRGX N/A
- WHF 21.05%
- EPS Growth
- CRGX N/A
- WHF N/A
- EPS
- CRGX N/A
- WHF 0.15
- Revenue
- CRGX N/A
- WHF $81,499,000.00
- Revenue This Year
- CRGX N/A
- WHF N/A
- Revenue Next Year
- CRGX N/A
- WHF N/A
- P/E Ratio
- CRGX N/A
- WHF $55.41
- Revenue Growth
- CRGX N/A
- WHF N/A
- 52 Week Low
- CRGX $3.00
- WHF $8.36
- 52 Week High
- CRGX $25.45
- WHF $12.42
- Technical
- Relative Strength Index (RSI)
- CRGX 59.56
- WHF 37.13
- Support Level
- CRGX $4.45
- WHF $8.36
- Resistance Level
- CRGX $4.51
- WHF $8.57
- Average True Range (ATR)
- CRGX 0.04
- WHF 0.14
- MACD
- CRGX -0.00
- WHF -0.02
- Stochastic Oscillator
- CRGX 76.00
- WHF 19.35
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
About WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.